Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
So if you stop taking them, you retain your controlled appetite?
Spoiler: nope.
They’re not a cure for anything.